The Dimebon data was from a small Russian study, correct? How much stock do you put in that? I'm anxious to see how the data stacks up after a U.S. trial. I don't have the guts to touch MDVN until then.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.